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Abstract
Objectives: To review the current evidence on the relationship between three pro-
posed mediators (comorbidities, hospital type, and treatment delays) for the relation-
ship between socioeconomic status (SES) and bladder cancer survival.
Materials and methods: Six different searches using OVID (Medline and Embase) 
were carried out to collate information available between the proposed mediators 
with both SES and survival in bladder cancer. This systematic review was conducted 
according to a pre-defined protocol and in line with the Preferred Reporting Items for 
Systematic Reviews and Meta-Analyses (PRISMA) guidelines.
Results: A total of 49 studies were included in the review across the six searches 
(one appeared in two searches). There was a wealth of studies investigating the re-
lationship between each of the proposed mediators with survival in bladder cancer 
patients. In general, a higher SES, lower comorbidities, and a larger hospital volume 
were all found to be associated with a decreased risk of death in bladder cancer 
patients. There was, however, a paucity of studies investigating the associations be-
tween these mediators and SES in bladder cancer patients.
Conclusions: To gain a deeper understanding of the relationship between SES and 
survival identified in several observational studies, further investigations into the re-
lationship between the proposed mediators and SES are warranted. Moreover, modi-
fiable mediators, eg, treatment delay, highlight the importance of the standardization 
of clinical care across SES groups for all bladder cancer patients.
K E Y W O R D S
bladder cancer, mediation, socioeconomic status, survival, systematic review
1  | INTRODUC TION
The survival of bladder cancer patients is dependent on many fac-
tors such as clinical variables, gender, diagnostic delay, geographical 
region, access to care, comorbidity, and risk factors such as smoking 
and occupational exposure.1 Many of these individual factors are as-
sociated with socioeconomic status (SES). Disparities in cancer inci-
dence and survival have been frequently observed among different 
socioeconomic groups for several types of cancer including bladder, 
stomach, liver, lips–mouth–pharynx, and lung.2,3
2  |     RUSSELL Et aL.
In bladder cancer, the link between SES and survival has been stud-
ied previously and patients with lower SES have been shown to have a 
decreased 5-year survival,4 overall survival,5 and higher relative risk of 
death.6 Null finding has also been observed for the risk of bladder-can-
cer-specific mortality.5 Around 75% of all bladder cancer patients have 
non-muscle-invasive bladder cancer (NMIBC) with the remaining 25% 
being diagnosed with muscle-invasive bladder cancer (MIBC). The main 
treatment choice for patients with NMIBC is usually transurethral re-
section of the bladder tumor (TURBT), Bacillus Calmette-Guerin (BCG) 
therapy or chemotherapy.7 For non-metastatic MIBC, the main treat-
ment choices are radical cystectomy, chemotherapy or radiotherapy.8
The exact mechanism behind the association between SES and 
survival is complex and unknown; however, a review by Quaglia 
et al. postulated that the link could be explained by factors relating 
to three main groups: diagnosis, treatment modalities, and patient 
characteristics.9 Despite this evidence, there remains paucity in de-
tailed studies and comprehensive clinical investigations to elucidate 
the underlying mechanisms behind this association. SES is a largely 
unmodifiable factor; therefore, identifying potential mediators of 
the association between SES and survival could be used as a founda-
tion for future interventions or recommendations to reduce the SES 
disparity seen in cancer survival.
Previously, using data from a cohort of Swedish bladder cancer 
patients, we found that Charlson Comorbidity Index (CCI), hospital 
type, and treatment delays mediated the association between SES 
and risk of death.10 On the basis of these results, the aim of this 
systematic review is to collate information from existing literature 
about the potential mediators (hospital type, comorbidities, and 
treatment delay) for the association between SES and survival in 
bladder cancer patients.
2  | MATERIAL S AND METHODS
Using similar methods as those described by Shanmugalingam et al,11 
six separate searches were performed to investigate the relationship 
of each potential mediator (hospital type, comorbidities, and treat-
ment delay) with both SES and survival in bladder cancer patients. 
The full protocol is outlined in the Appendix. Figure 1 demonstrates 
the directed acyclic graph with each arrow representing a search 
carried out. The six searches were as follows: (1) SES and survival, 
(2) SES and hospital type, (3) Hospital type and survival, (4) SES and 
comorbidities, (5) comorbidities and survival, (6) SES and treatment 
delay. Number 7 in Figure 1 (the association between treatment 
delay and survival), however, was not carried out as the results are 
presented elsewhere.12
2.1 | Search strategies
The online database Ovid Gateway was used to search both Embase 
and Medline for relevant studies (for which the search items are 
explained in detail in the appendix). Searches were performed 
to include only articles in English, with human subjects, and pub-
lished from the year 2000 onwards. Searches were performed in 
November 2019.
Articles were included if: they were specific to bladder cancer, 
they were not conference abstracts or commentaries and the full 
text was available. Studies were excluded if they did not investigate 
the relevant exposure and outcome variables for each mediator and/
or were deemed of low quality after quality assessment (as explained 
below). Reviews were included to allow for the inclusion of as much 
information as possible including data from studies that might not 
have been captured within the current search strategy. When sys-
tematic reviews were already conducted according to the PRISMA 
guidelines, these were considered to overwrite individual studies 
included in the systematic review and the results were presented 
as a whole. Initially, titles were screened for relevance, then ab-
stracts and full texts were subsequently screened. Data extraction 
was performed on a per mediator basis in which the year, country of 
study, number of patients, method for assessing comorbidities or so-
cioeconomic status, and summary measures of results (e.g. survival 
F I G U R E  1   Directed acyclic graph with each number depicting a different association investigated. Socioeconomic status is the exposure 
variable, death is the outcome variable, while hospital type, comorbidities, and treatment delay are the potential mediators
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proportions, odds ratios or hazard ratios) were recorded in separate 
tables. All screening was performed by BR and MVH and data ex-
traction by BR. All studies were described and compared in a narra-
tive manner with no quantitative analyses taking place.
This review was conducted in accordance with the Preferred 
Reporting Items for Systematic Reviews and Meta-Analyses 
(PRISMA) guidelines.13 The quality of the studies was assessed using 
Risk of Bias in Non-Randomized Studies – Interventions (ROBINS-I) 
for all observational studies with death as the outcome.14 The 
systematic reviews were assessed using A Measurement Tool to 
Assess Systematic Reviews 2 (AMSTAR 2),15 while the narrative re-
views were assessed using the Scale for the quality Assessment of 
Narrative Review Articles (SANRA).16
3  | RESULTS
A total of 1168 studies were initially extracted from the searches. A 
summary of the frequency of studies identified and subsequently in-
cluded in the analysis for each search is depicted in Figure 2. No stud-
ies were identified for inclusion for the associations between SES and 
both comorbidities and hospital type (arrows 2 and 4, Figure 2).
3.1 | SES and survival
After screening the 178 studies identified in the search, 14 studies 
were deemed suitable for inclusion when investigating the associa-
tion between SES and survival (both overall and bladder cancer-
specific) in bladder cancer patients5,9,17-28 (Table 1). The main reason 
for the exclusion of studies was the investigation of post-operative 
complications rather than survival specifically. Included in the analy-
sis were 2 reviews and 12 cohort studies.
Seven of the studies included both NMIBC and MIBC patients 
within their analyses and four of these concluded an association be-
tween a lower SES and reduced overall survival5,18,20,23,28 (Table 1). 
The two studies which did not observe this result were those of 
Eberle et al and Syriopoulou, although the latter only presented raw 
data with no level of significance reported for any results.19,24 Four 
of the studies included MIBC only22,25-27 and one study included 
metastatic MIBC patients only.21 All five concluded an association 
between a lower SES and reduced overall survival. None of the stud-
ies included any of the proposed mediators (comorbidities, hospital 
type or treatment delay) within their analyses.
3.2 | Hospital type and survival
Fifteen studies investigating the association between hospital 
type and the survival of bladder cancer patients were identi-
fied29-43 (Table 2). Two studies were reviews, the remaining thir-
teen were cohort studies. All of the studies defined the “type” of 
hospital based on the volume of bladder cancer patients treated 
(namely the number of radical cystectomies per year). The stud-
ies by Bajaj et al33 and Scarberry et al35 additionally investigated 
whether the hospital was an academic center or not. The review by 
Nuttal et al29 noted that the approach to defining hospital volume 
was heterogeneous across studies, with some using the annual 
number of radical cystectomies and others using the number of 
radical cystectomies within the study period. All studies included 
patients with MIBC either undergoing radical cystectomy or cura-
tive radiotherapy (including chemoradiation therapy); the studies 
F I G U R E  2   Study selection process. BC, bladder cancer; SES, socioeconomic status














































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































10  |     RUSSELL Et aL.
by Birkmeyer et al32 and Hounsome et al36 additionally included 
NMIBC patients.
Eleven of the 13 observational studies concluded that either a 
larger hospital volume (as defined by each study) was associated with 
increased survival, or a smaller hospital volume (as defined by each 
study) was associated with a decreased survival.30-32,34-38,40,43,44 
The definition for a high volume center ranged from > 3.25 to 25-66 
cystectomies per year. The study by Bajaj et al33 utilized academic vs 
non-academic center type as the exposure variable. They concluded 
that treatment with curative radiation therapy or concurrent chemo-
radiation therapy at an academic hospital was not associated with 
improved overall survival when compared to the same treatment at a 
non-academic hospital. Moreover, the study by de Vries et al42 looked 
at 30-day mortality post-radical cystectomy between high and low 
volume centers (1.8% vs 3.5%, respectively) but deemed the differ-
ence non-significant. The results from the studies within the review 
by Nuttal et al were mixed with some stating an association between 
hospital volume and survival while others did not.29 However, the au-
thors state that “on average” patients undergoing a radical cystectomy 
at a high-volume center have increased survival compared to those at 
a low-volume center. The other review by Williams et al,39 which was 
published 15 years after the Nuttal review, concluded that most stud-
ies reported better survival outcomes in high volume centers.
3.3 | Comorbidities and survival
709 studies were extracted from the search of which 19 were deemed 
suitable for inclusion (Table 3). These studies included 1 review45 and 
18 cohort studies46-63 (of which eight were from single-center data)63). 
Thirteen of the 19 studies investigated the association between co-
morbidity and survival in patients undergoing radical cystectomy, one 
of which also looked at MIBC patients who had undergone external 
beam or interstitial radiotherapy.53 Three studies looked at this as-
sociation in both NMIBC and MIBC patients; however, the study by 
Safarti et al51 did not stratify the analyses by NMIBC/MIBC and so 
the results could not be presented separately. Two studies looked 
at NMIBC patients only and the remaining study looked at patients 
treated with TURBT; the latter study did not describe more detailed 
stage information beyond NMIBC.46 None of the studies investigating 
comorbidities and survival included an SES indicator in their analyses.
For all MIBC patients and those undergoing curative treatment 
(radical cystectomy or external beam radiotherapy), 12 of the stud-
ies concluded an association between increasing comorbidity (as 
defined by each study) and an increased risk of overall death.48-50,53-
60,62 Three studies stated the same direction of association for can-
cer-specific death.54,57,61
The ways in which the studies measured comorbidity for the 
radical cystectomy patients varied as can be seen in Table 3. Some 
examples of measurements used include CCI, age-adjusted CCI 
(ACCI), Adult Comorbidity Evaluation-27 (ACE-27), American Society 
of Anesthesiologists (ASA), Eastern Cooperative Oncology Group 
Performance Status (ECOG PS), and Elixhauser index (EI). A common 
theme among several of the studies was the comparison of the predic-
tive value of these comorbidity indices on survival.48,54,55,62 The most 
recent of the two studies by Mayr et al investigated ASA, ECOG, ACE-
27, CCI, and ACCI.54 Increasing values of all five comorbidity indicators 
were associated with cancer independent mortality post-cystectomy. 
Furthermore, ASA (score of 3-4), ECOG,2,3 ACE27,3 and ACCI (>5) 
were all associated with an increased risk of cancer-specific mortality 
after radical cystectomy. Similarly, Boorjian et al compared the predic-
tive capabilities of CCI, ASA, ECOG, and EI indices on perioperative 
and 5-year all-cause mortality in radical cystectomy patients.62 They 
concluded that all four indices were independent predictors of 5-year 
mortality, but only ASA, ECOG, and EI were predictors of periopera-
tive mortality (within 90-days post-cystectomy).
Three of the studies which included NMIBC patients described 
a positive association between comorbidity and an increased risk of 
overall death.57,59,63 None of the studies investigating NMIBC pa-
tients concluded the same association when considering cancer-spe-
cific death. Although Sarfati et al did not stratify their analyses by 
NMIBC and MIBC patients, they noted a positive association be-
tween almost all the comorbidities investigated with overall mortal-
ity in urological cancers (renal and bladder).51
Two studies specifically investigated chronic kidney disease 
(CKD) as a major contributing factor to the link between comorbid-
ity status and survival in bladder cancer patients.49,63 The study by 
Li et al encompassed NMIBC patients who underwent TURBT, both 
with and without CKD.63 The authors concluded that bladder cancer 
patients with CKD had increased odds of all-cause death when com-
pared to patients without CKD.
3.4 | SES and treatment delay
Two studies were deemed suitable for inclusion when investigating 
the relationship between SES and treatment delay1,5 (Table 4). The 
study by Jacobs et al was a more general review looking into the 
disparities in survival in bladder cancer patients. The authors delved 
into factors such as SES and access to care stating that patients 
from a lower SES group may have their treatments delayed due to 
a variety of factors such as weak social support, lack of transporta-
tion, and cultural behaviors.1 There was, however, no quantification 
of this association available. Meanwhile, the study by Begum et al5 
concluded that there were no differences in delay times among so-
cio-economic groups for the delay categories of symptom onset to 
first referral, referral to first attendance at hospital, first hospital at-
tendance to first treatment (TURBT), and the total delay from onset 
of symptoms to first treatment.
3.5 | Quality of the included studies
Overall, the majority of the observational studies assessed using the 
ROBINS-I tool were deemed to have a low risk of bias (Tables S1-S3, 
Appendix). A few had a moderate risk of bias; however, these tended 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































16  |     RUSSELL Et aL.
to be the studies that had not sufficiently adjusted for all possible con-
founding variables or stated crude survival proportions only. Using 
the AMSTAR criteria, there was deemed to be a moderate level of 
confidence in the results from the four systematic reviews (Figure S1, 
Appendix). There was, however, a paucity in pre-defined study pro-
tocols detailing the search, definition of inclusion and exclusion crite-
ria, and all failed to assess the risk of bias of the studies within each 
relative review. The two narrative reviews were both deemed of good 
quality according to the SANRA criteria (Figure S2, Appendix).
4  | DISCUSSION
This review collated information from existing literature about the 
potential mediators (hospital type, comorbidities, and treatment 
delay) for the association between SES and survival in bladder can-
cer patients by specifically evaluating how each of them is associ-
ated with SES and/or bladder cancer survival. Overall, the review 
suggested associations between each of the three potential media-
tors with survival. However, there was a paucity of information relat-
ing to the association between SES and the mediators investigated.
One notable finding was the heterogeneity in which SES was as-
sessed. However, there is no perfect way to assess SES levels and 
the method used by a certain study may be limited by the variables 
available in a particular dataset. An example of another possible 
proxy for SES is educational level; however, this was not utilized by 
any of the studies in this review. Despite the use of several types of 
SES indicators, the results from the current review suggest that a 
lower SES is associated with reduced survival. The only study which 
did not reach the same conclusion was by Eberle et al which used a 
two-step method to determine SES based on an existing discrimina-
tion index for Bremen.19
4.1 | Hospital type
All of the 15 studies which investigated the association between hospi-
tal type and overall survival defined the hospital type in terms of hospi-
tal volume, while two additionally assessed academic vs non-academic 
centers. No studies were found to investigate SES and hospital type 
for bladder cancer specifically; however, a study by Chang et al inves-
tigated this research question for breast cancer patients.64 They con-
cluded that patients with a lower SES were more likely to be treated at 
a low-volume hospital and be operated on by a low-volume surgeon. 
Therefore, to establish whether a similar association exists in bladder 
cancer patients, future studies are needed that also adjust for the in-
teraction with other factors such as distance to treatment facilities.65
4.2 | Comorbidity
Although no studies looking at SES and comorbidity were identi-
fied, outside of the bladder cancer setting evidence does exist for 
an association between these two variables. For example, a more 
generalized systematic review and meta-analysis66 identified 24 
cross-sectional studies and found SES to be assessed by many meas-
ures including education, deprivation, income, occupational social 
class, social class (not defined), literacy score, employment status, 
and self-reported poverty. Low education was associated with 64% 
increased odds of multimorbidity (OR: 1.64, 95% CI: 1.41-1.91); 
deprivation was also linked to risk of multimorbidity, although the 
evidence for income was mixed. The authors also stated that there 
was heterogeneity in the assessment of multimorbidity across the 
studies.
We also observed heterogeneity in the methods for assessing 
comorbidity among the studies. Even though many methods exist, 
results from this review would suggest that most measures of co-
morbidity have predictive capabilities regarding survival in bladder 
cancer patients who have undergone radical cystectomy.
There was also heterogeneity in the patients included within the 
studies. Most of the studies investigated patients who had under-
gone radical cystectomy, but this included both NMIBC and MIBC 
patients. Other studies included NMIBC patients only or patients 
who had undergone TURBT (with no information about their stag-
ing). This may have had an effect on the type of comorbidity mea-
sures which were utilized by the studies.
4.3 | Treatment delay
The paucity of studies investigating SES and treatment delay, to-
gether with the literature on SES, diagnostic delay, and variation in 
emergency presentation67 suggests a complex mediation of SES and 
survival in bladder cancer. Thus, more advanced disease at diagnosis 
in patients with lower SES affects further treatment possibilities.68
4.4 | Strengths and limitations
Several of the studies, in particular those investigating the associa-
tion between comorbidities and survival, were single-center stud-
ies.52,57-63 Possible reasons for this include the lack of a universal 
comorbidity score and that different scores perform better from 
one disease or treatment or surgery to another. These studies may 
not have the same degree of external validity seen in nationwide 
or larger studies. Nonetheless, single-center studies are still crucial 
in healthcare research as they can capture data on a more granu-
lar level when compared to larger cohort studies. This review addi-
tionally benefitted from the inclusion of many large cohort studies. 
These studies are inclusive of heterogeneous populations, which is 
especially important when studying factors such as SES.
A large proportion of the studies, particularly when looking at 
comorbidities, included patients undergoing radical cystectomy. 
Therefore, a limitation to the current review is the low number of 
studies that included NMIBC patients, or those undergoing alternate 
treatments. Some studies did, however, include patients undergoing 
     |  17RUSSELL Et aL.
radiotherapy. It is important to note, however, that this may also be 
a limitation since patients who receive radiotherapy often do so as a 
result of being too frail for surgery and hence may skew the results 
for survival. Furthermore, none of the studies within this review 
used a formal mediation analysis. It is also possible that some litera-
ture may have been missed if studies included the research question 
of interest as a secondary or tertiary research question and were 
subsequently not picked up during title and abstract screening.
Meta-analyses were not deemed suitable in this review due to 
the heterogeneity of the studies identified.
5  | CONCLUSIONS
The studies identified in this review imply associations between the 
possible mediators of the association between SES and survival in 
bladder cancer patients (hospital type, comorbidities, and treatment 
delay). While a low SES was found to be associated with decreased 
survival in numerous studies (despite heterogeneous methods used 
to assess SES), this review has highlighted a paucity of studies investi-
gating mediators for this association. Further studies investigating the 
relationship between the proposed mediators and SES using logistic 
regression models are warranted for a deeper understanding of the 
relationship between SES and survival. With such an understanding, 
modifiable mediators, eg, treatment delay, may be identified and fur-
ther motivate the standardization of clinical care across SES groups.
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